Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Orexo AB

Market Cap 733M 76.55M 66.75M 61.82M 57.87M 109M 7.22B 109M 284M 3.56B 287M 281M 12.35B P/E 2026 *
-2.33x
P/E 2027 * -2.91x
Enterprise Value 535M 55.88M 48.73M 45.13M 42.24M 79.23M 5.27B 79.71M 207M 2.6B 210M 205M 9.01B EV / Sales 2026 *
20.6x
EV / Sales 2027 * 21.9x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 week+1.45%
Current month+2.44%
1 month+11.70%
3 months-7.69%
6 months-10.83%
Current year-30.23%
1 week 20.5
Extreme 20.5
22.55
1 month 18.58
Extreme 18.58
22.55
Current year 17.52
Extreme 17.52
36
1 year 17.5
Extreme 17.5
43.4
3 years 8.79
Extreme 8.79
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap.
04/09/25Free

Chief Executive Officer

1,393 0.0040%
04/09/25Buy

Chief Executive Officer

6 0.0000%
03/09/25Free 149 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.45%+6.49%+130.77% 76.55M
-1.36%-4.35%+43.61%+4.16% 281B
-0.11%-0.26%+21.98%-14.78% 66.27B
+1.30%+5.71%+2.36%-8.19% 8.24B
-0.03%-1.37%+28.97%+95.97% 8.13B
-1.92%-1.02%-3.55%+1.99% 4.45B
-2.69%-1.42%-24.73%+36.12% 3.71B
+8.33%+2.08%-1.03%+13.01% 3.42B
+1.84%-0.07%+34.65%+31.42% 2.58B
-1.01%-2.64%+4.03%-29.74% 1.92B
Average +0.44%-0.69%+11.28%+26.07% 38B
Weighted average by Cap. -0.96%-4.30%+36.74%+2.96%

Financials

2026 *2027 *
Net sales 26M 2.71M 2.37M 2.19M 2.05M 3.85M 256M 3.87M 10.08M 126M 10.19M 9.97M 438M 27M 2.82M 2.46M 2.28M 2.13M 4M 266M 4.02M 10.46M 131M 10.58M 10.35M 455M
Net income -322M -33.61M -29.31M -27.14M -25.41M -47.65M -3.17B -47.94M -125M -1.56B -126M -123M -5.42B -259M -27.04M -23.57M -21.83M -20.44M -38.33M -2.55B -38.56M -100M -1.26B -101M -99.31M -4.36B
Net Debt -198M -20.67M -18.02M -16.69M -15.62M -29.3M -1.95B -29.48M -76.74M -960M -77.58M -75.92M -3.33B -142M -14.82M -12.92M -11.97M -11.21M -21.01M -1.4B -21.14M -55.03M -688M -55.64M -54.45M -2.39B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
65
Date Price Change Volume
18/06/26 21.00 kr 0.00% 4,348
17/06/26 21.00 kr -0.94% 22,217
16/06/26 21.20 kr -0.70% 32,013
15/06/26 21.35 kr +3.14% 34,104
12/06/26 20.70 kr +5.18% 17,790
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!